



copy

PTO/SB/17 (12-04)  
Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

## FEE TRANSMITTAL for FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 230.00

### Complete if Known

Application Number	09/758,173
Filing Date	January 12, 2001
First Named Inventor	DARRELL R ANDERSON
Examiner Name	
Art Unit	1644
Attorney Docket No.	037003-0276603

### METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account      Deposit Account Number: 033975      Deposit Account Name: See 1 in Addendum

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below      ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayment of fees(s) under 37 CFR 1.16 and 1.17      ☐ Credit any overpayments

WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

### FEE CALCULATION

#### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fee Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	100	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

#### 2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims - 20 or HP = Extra Claims X Fee (\$) = Fee Paid (\$)      Multiple Dependent Claims  
HP = highest number of total claims paid for, if greater than 20      Fee (\$)      Fee Paid (\$)

Indep. Claims - 3 or HP = Extra Claims X Fee (\$) = Fee Paid (\$)  
HP = highest number of independent claims paid for, if greater than 3

#### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets - 100 = Extra Sheets /50= Number of each additional 50 or fraction thereof x Fee (\$) = Fee Paid (\$)  
(round up to a whole number) x 250.00 =

#### 4. OTHER FEE(S)

Non-English Specification, 130 fee (no small entity discount)

Other: Petition Fee - 37 CFR 1.17(h) - Certificate of Correction Fee - \$130.00 and 100.00

230.00

#### SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	40944	Telephone	703905.2144
Name (Print/Type)	Thomas A. Cawley, Jr. Ph.D.	Date	June 10, 2005		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


JUN 16 2005



## Addendum

1. PILLSBURY WINTHROP SHAW PITTMAN LLP

Attorney Docket: 037003-0276603  
Client Reference: 1995-30-0233D2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re ANDERSON et al.

Patent No.: 6,893,638 *B2*

Application No.: 09/758,173

Issued: May 17, 2005

Filed: January 12, 2001

Title: METHODS FOR TREATING B CELL LYMPHOMA USING CD80-SPECIFIC ANTIBODIES

**PETITION PURSUANT TO 37 C.F.R. §1.183 AND REQUEST FOR  
CERTIFICATE OF CORRECTION**

Office of Petitions  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

06/14/2005 SDENBOB1 00000001 033975 6893638  
01 FC:1811 100.00 DA

Sir:

This request and attached documents replaces the defective request and documents filed with the USPTO on 11 June 2005.

The patentees respectively request that the present petition be granted for the identification of the assignee's name in connection with the above-identified patent, wherein the omission of the assignee's name on the Form PTOL-85B was an inadvertent error.

The patentees request that 37 C.F.R. §3.81(a) be waived for the inclusion of the assignee's name after the issuance of the patent. The present patent is a divisional of U.S. Patent Appl. No. 08/487,550, which was assigned from the inventors to IDEC Pharmaceuticals Corporation, as recorded on May 23, 1996, at Reel No. 7832/Frame No. 0646 (see Appendix A) Further, a change of name from IDEC Pharmaceuticals Corporation to Biogen IDEC Inc. was recorded on August 6, 2004, at Reel No. 015044/Frame No. 0873 (see Appendix B) Both assignments were submitted for recordation with USPTO before the time of issuance.

In view of the foregoing, the patentees submit herewith a Certificate of Correction Form PTO-1050 to indicate that, at the time of issuance, U.S. Patent No. 6,893,638 was assigned to Biogen IDEC Inc. Pursuant to 37 C.F.R. §1.183 and 1.323, the patentees have enclosed herewith the fees required by 37 C.F.R. §1.17(h) (\$130.00) and 1.20(a) (\$100.00).

The USPTO also erred with respect to sequence identifications numbers in claims 1 and 3 of the issued patent. The phrase "SEQ ID NOs 5-6 and 7-3" should read "SEQ ID

06/13/2005 SDENBOB1 00000097 033975 09758173  
01 FC:1811 100.00 DA  
Adjustment date: 06/14/2005 SDENBOB1  
06/13/2005 SDENBOB1 00000097 033975 09758173  
01 FC:1811 100.00 CR

06/13/2005 SDENBOB1 00000097 033975 09758173  
02 FC:1462 400.00 DA

JUN 16 2005

Attorney Docket: 037003-0276603  
Client Reference: 1995-30-0233D2

NOS 5-6 and 7-8" in claims 1 and 3. The correct language (SEQ ID NOS: 5-6 and 7-8 was present throughout prosecution of the application prior to the issuance of the patent.

Although the patentees believe additional fees (beyond the amount presented herein) are not necessary for consideration of this petition and entry of the certificate of correction as requested, should the patent office determine additional fees are due, the commissioner is authorized to charge such fees to the Deposit Account No. 03-3975.

Respectfully submitted,



THOMAS A. CAWLEY, JR., Ph.D.  
Reg. No. 40944  
Tel. No. (703) 905-2144  
Fax No. (703) 905-2500

PILLSBURY WINTHROP SHAW PITTMAN LLP  
P.O. Box 10500  
McLean, VA 22102  
June 10, 2005

TAC/wks

JUN 16 2005

Staple  
Here  
Only  
Printer's  
Trim  
Line →

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,893,638 *B2*  
DATED : May 17, 2005  
INVENTOR(s) : ANDERSON et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face of the patent, after (76), the following should be inserted.

-- (73) Assignee: **Biogen Idec Inc.**, Cambridge, MA --

At column 57, line 42, the text of "sequences of SEQ ID NOs. 5-6 and 7-3 respectively); and" should be corrected to

-- sequences of SEQ ID NOs. 5-6 and 7-8 respectively); and --.

At column 58, line 33, the text of "sequences of SEQ ID NOs. 5-6 and 7-3 respectively); and" should be corrected to

-- sequences of SEQ ID NOs. 5-6 and 7-8 respectively); and --.

MAILING ADDRESS OF SENDER

PATENT NO. 6,893,638

Thomas A. Cawley, Jr. Ph.D.  
Reg. No. 40,944  
Pillsbury Winthrop Shaw Pittman LLP  
Intellectual Property Group  
P.O. Box 10500  
McLean, VA 22102



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

MAY 29, 1996

PTAS  
BURNS, DOANE, SWECKER & MATHIS, LLP  
ROBIN L. TESKIN, ESQ.  
POST OFFICE BOX 1404  
ALEXANDRIA, VA 22313-1404



\*100181709A\*

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/23/1996

REEL/FRAME: 7832/0646  
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ANDERSON, DARRELL R.

DOC DATE: 11/13/1995

ASSIGNOR:

BRAMS, PETER

DOC DATE: 11/13/1995

ASSIGNOR:

HANNA, NABIL

DOC DATE: 11/13/1995

ASSIGNOR:

SHESTOWSKY, WILLIAM S.

DOC DATE: 11/14/1995

ASSIGNEE:

IDEC PHARMACEUTICALS CORPORATION  
11011 TORREYANA ROAD  
SAN DIEGO, CALIFORNIA 92121

SERIAL NUMBER: 08487550  
PATENT NUMBER:

FILING DATE: 06/07/1995  
ISSUE DATE:

DOCKETED  
Date 012712-131

7832/0646 PAGE 2

JACQUELINE MOORE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

## ASSIGNMENT (JOINT)

THIS ASSIGNMENT, by DARRELL R. ANDERSON, PETER BRAMS, NABIL HANNA and BILL SHESTOWSKY (hereinafter referred to as "the Assignors"), residing at 1851 NAVAJO PLACE, ESCONDIDO, CA 92029; 4260 3RD AVENUE, #101, SAN DIEGO, CA 92103; 3255 FORTUNA RANCH ROAD, OLIVENHAIN, CA 92024; 1155 THOMAS AVENUE, SAN DIEGO, CA 92109; 4311 ROBBINS STREET, SAN DIEGO, CA 92122; and 1225 VIA MONTORO, ENCINITAS, CA 92024, respectively, witnesseth:

WHEREAS, the Assignors have invented certain new and useful improvements in MONKEY MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS IMMUNOSUPPRESSANTS set forth in an application for Letters Patent of the United States, [ ] having an oath or declaration executed on even date herewith; [X] bearing Application No. 08/487,550, and filed on JUNE 7, 1995; and

WHEREAS, IDEC PHARMACEUTICALS CORPORATION, a corporation duly organized under and pursuant to the laws of CALIFORNIA and having its principal place of business at 11011 TORREYANA ROAD, SAN DIEGO, CA 92121 (hereinafter referred to as "the Assignee"), is desirous of acquiring the entire right, title, and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignors have sold, assigned, transferred, and set over, and by these presents do sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents of the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignors had this sale and assignment not been made;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignors are the sole and lawful owners of the entire right, title, and interest in and to the inventions and application for Letters Patent above-mentioned, and that the same are unencumbered, and that the Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns that the Assignors will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said inventions or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including



interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of Letters Patent for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the Assignee as the Assignee of said inventions, the Letters Patent to be issued for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date 11/13/95 Name of Assignor D. R. Anderson  
Darrell R. ANDERSON

Date 11-13-95 Name of Assignor Peter Brams  
Peter BRAMS

Date 11/13/95 Name of Assignor Nabil Hanna  
Nabil HANNA

Date 11/14/95 Name of Assignor William S. Shestowsky  
Bill SHESTOWSKY

05-23-1996



100181709

581-40  
SHEET

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Attorney's Docket No. 012712-131

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

- (1) Darrell R. Anderson  
(2) Peter Brams  
(3) Nabil Hanna  
(4) William S. Shestowsky

MRD  
5-23-96

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name

Other: \_\_\_\_\_

Execution Date: (1) 11/13/95 (2) 11/13/95 (3) 11/13/95  
(4) 11/14/95

2. Name and address of receiving party(ies):

Name: IDEC Pharmaceuticals Corporation

Address: 11011 Torreyana Road

San Diego, CA 92121

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No.(s)

08/487,550

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Robin L. Teskin, Esq.

Address: Burns, Doane, Swecker & Mathis, LLP

Post Office Box 1404

Alexandria, Virginia 22313-1404

6. Total number of applications and patents involved: 1

620 GT 05/28/96 08487550

1 581 40.00 CK 012712-131 ✓

7. Total fee (37 CFR 3.41): \$40.00

☒ Enclosed

☒ Authorized to be charged to deposit account, if necessary

8. Deposit account number:

02-4800

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

40E chg  
30 spec fee

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Robin L. Teskin  
Name of Person Signing

Robin L. Teskin  
Signature

May 23, 1996  
Date

Total number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

chg 30  
spec  
fee



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND  
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 03, 2004

PTAS



\*700106103A\*

PILLSBURY WINTHROP LLP  
THOMAS A. CAWLEY, JR.  
P.O. BOX 10500  
INTELLECTUAL PROPERTY GROUP  
MCLEAN, VA 22102

### UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/06/2004

REEL/FRAME: 015044/0873  
NUMBER OF PAGES: 7

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

IDEC PHARMACEUTICALS CORPORATION

DOC DATE: 11/12/2003

ASSIGNEE:

BIOGEN IDEC INC.  
3030 CALLAN ROAD  
SAN DIEGO, CALIFORNIA 92121

SERIAL NUMBER: 07431426

FILING DATE: 11/03/1989

PATENT NUMBER:

ISSUE DATE:

TITLE: ANTI-IDIOTYPE ANTIBODIES TO HUMAN MELANOMA-ASSOCIATED PROTEOGLYCAN ANTIGEN

SERIAL NUMBER: 07735064

FILING DATE: 07/25/1991

PATENT NUMBER:

ISSUE DATE:

TITLE: CHIMERIC ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07735069 FILING DATE: 07/25/1991  
PATENT NUMBER: ISSUE DATE:  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 07856281 FILING DATE: 03/23/1992  
PATENT NUMBER: ISSUE DATE:  
TITLE: CHIMERIC ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07912292 FILING DATE: 07/10/1992  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07977691 FILING DATE: 11/13/1992  
PATENT NUMBER: ISSUE DATE:  
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE FOR ENHANCEMENT OF  
EXPRESSION OF CO-LINKED GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS  
COMPRISING SAME

SERIAL NUMBER: 08476674 FILING DATE: 06/07/1995  
PATENT NUMBER: ISSUE DATE:  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08746361 FILING DATE: 11/08/1996  
PATENT NUMBER: ISSUE DATE:  
TITLE: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN  
ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS

SERIAL NUMBER: 08933359 FILING DATE: 09/18/1997  
PATENT NUMBER: ISSUE DATE:  
TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR  
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09082472 FILING DATE: 05/21/1998  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09149479 FILING DATE: 09/08/1998  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES  
DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-  
ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 09615796 FILING DATE: 07/13/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION  
STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND  
EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 09834933 FILING DATE: 04/16/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN  
COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND  
RADIOTHERAPY

SERIAL NUMBER: 09850165 FILING DATE: 05/08/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09877065 FILING DATE: 06/11/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND  
DIAGNOSIS OF OVARIAN CARCINOMAS

SERIAL NUMBER: 09971631 FILING DATE: 10/09/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION  
STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND  
EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 60057831 FILING DATE: 09/08/1997  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES  
DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-  
ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 60109607 FILING DATE: 11/23/1998  
PATENT NUMBER: ISSUE DATE:  
TITLE: TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 60134848 FILING DATE: 05/19/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: OVERCOMING BARRIERS TO ADENOVIRUS VECTOR-MEDIATED GENE THERAPY FOR  
CYSTIC FIBROSIS

SERIAL NUMBER: 60148288 FILING DATE: 08/11/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: NEW CLINICAL PARAMETERS FOR DETERMINING HEMATOLOGIC TOXICITY PRIOR  
TO RADIOIMMUNOTHERAPY

SERIAL NUMBER: 60185390 FILING DATE: 02/28/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD FOR PRAPARING ANTI-MIF ANTIBODIES

SERIAL NUMBER: 60189050 FILING DATE: 03/14/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: TWO MONOCLONAL ANTIBODIES THAT BIND PHOSPHATIDYL SERINE AND A  
METHOD OF KILLING TUMOR CELLS

SERIAL NUMBER: 60193467 FILING DATE: 03/31/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES AND ANTI-CD20 FOR THE  
TREATMENT OF B-CELL LYMPHOMA

SERIAL NUMBER: 60199365 FILING DATE: 04/25/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL  
NERVOUS SYSTEM LYMPHOMAS

015044/0873 PAGE 4

SERIAL NUMBER: 60209584	FILING DATE: 06/06/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: NON-AGONISTRIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF	
SERIAL NUMBER: 60210451	FILING DATE: 06/09/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND DIAGNOSIS OF OVARIAN CARCINOMAS	
SERIAL NUMBER: 60212668	FILING DATE: 06/20/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCIES AND AUTOMMUNE DISEASES USING ANTI-CD20 ANTIBODY/RADIOLABLED ANTI-CD22 ANTIBODY COMBINATION	
SERIAL NUMBER: 60213252	FILING DATE: 06/22/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR CELL KILLING OF TARGET CELLS	
SERIAL NUMBER: 60217706	FILING DATE: 07/12/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTOI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPETICS AND RADIOTHERAPY	
SERIAL NUMBER: 60233607	FILING DATE: 09/18/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES COMPRISING CD40L ANTAGONIST AND ANTIBODIES TO B7,CD19,CD20,CD22,CD23	
SERIAL NUMBER: 60233625	FILING DATE: 09/18/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: METHOD FOR PREPARING ANTI-MIF ANTIBODIES	
SERIAL NUMBER: 60241022	FILING DATE: 10/20/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: VARIANT LGG3 RITUXAN AND THERAPEUTIC USE THEREOF	
SERIAL NUMBER: 60257147	FILING DATE: 12/22/2000
PATENT NUMBER:	ISSUE DATE:
TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION	
SERIAL NUMBER: 60264318	FILING DATE: 01/29/2001
PATENT NUMBER:	ISSUE DATE:
TITLE: MODIFIED ANTIBODIES AND METHODS OF USE	
SERIAL NUMBER: 60280139	FILING DATE: 04/02/2001
PATENT NUMBER:	ISSUE DATE:
TITLE: EXPRESSION OF GNTIII IN A RECOMBINANT ANTI-CD20 CHO PRODUCTION CELL LINE: EXPRESSION OF ANTIBODIES WITH ALTERED GLYCOFORMS LEADS TO AN INCREASE IN ADCC THROUGH HIGHER AFFINITY FOR FCYRIII	

015044/0873 PAGE 5

SERIAL NUMBER: 60300063 FILING DATE: 06/25/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

SERIAL NUMBER: 60303813 FILING DATE: 07/10/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: INHIBITION OF APOPTOSIS PROCESS AND IMPROVEMENT OF CELL PERFORMANCE

SERIAL NUMBER: 60331187 FILING DATE: 11/09/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: ANTI CD 80 AND RITUXIMAB COMBINATION THERAPY OF B-CELL LYMPHOMA

SERIAL NUMBER: 60331481 FILING DATE: 11/16/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: POLYCLONAL EXPRESSION OF ANTIBODIES

SERIAL NUMBER: 60341860 FILING DATE: 12/21/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

SERIAL NUMBER: 60357140 FILING DATE: 02/19/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OR  
THERAPEUTICS

SERIAL NUMBER: 60367727 FILING DATE: 03/28/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND  
DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60381328 FILING DATE: 05/20/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND  
DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60386746 FILING DATE: 06/10/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES UPREGULATED IN BREAST CANCER AND USE THEREOF AS TARGETS FOR  
NOVEL THERAPIES AND DIAGNOSTIC AGENTS

SERIAL NUMBER: 60386747 FILING DATE: 06/10/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND  
DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60386748 FILING DATE: 06/10/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

015044/0873 PAGE 6

SERIAL NUMBER: 60386759 FILING DATE: 06/10/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OF  
THERAPEUTICS

SERIAL NUMBER: 60390191 FILING DATE: 06/21/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: BUFFERED FORMULATIONS FOR CONCENTRATING ANTIBODIES

SERIAL NUMBER: 60396082 FILING DATE: 07/17/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OF  
THERAPEUTICS

SERIAL NUMBER: 60396141 FILING DATE: 07/17/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

SERIAL NUMBER: 60396255 FILING DATE: 07/17/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES UPREGULATED IN BREAST CANCER

SERIAL NUMBER: 60400687 FILING DATE: 08/05/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: POLYCISTRONIC EXPRESSION OF ANTIBODIES

SERIAL NUMBER: 60405318 FILING DATE: 08/23/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES UPREGULATED IN BREAST CANCER

SERIAL NUMBER: 60405319 FILING DATE: 08/23/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

SERIAL NUMBER: 60410506 FILING DATE: 09/13/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD OF PURIFYING ANTIBODIES BY SIMULATED MOVING BED  
CHROMATOGRAPHY

SERIAL NUMBER: 60427564 FILING DATE: 11/20/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND  
DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60428274 FILING DATE: 11/22/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING  
NOVEL THERAPEUTICS

SERIAL NUMBER: 60452928 FILING DATE: 03/10/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES



015044/0873 PAGE 7

SERIAL NUMBER: 09238741 FILING DATE: 01/28/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: PRODUCTION OF TETRAVALENT ANTIBODIES

SERIAL NUMBER: 09259337 FILING DATE: 03/01/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: RADIOLABELING KIT AND BINDING ASSAY

SERIAL NUMBER: 09259338 FILING DATE: 03/01/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: KIT FOR RADIOLABELING LIGANDS WITH YTTRIUM-90

SERIAL NUMBER: 09435992 FILING DATE: 11/08/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN  
COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND  
RADIOTHERAPY

SERIAL NUMBER: 09447594 FILING DATE: 11/23/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 09576424 FILING DATE: 05/22/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF CROHN'S DISEASE USING ANTI-CD80 ANTIBODIES THAT DO NOT  
INHIBIT THE BINDING OF CD80 ANTIGEN TO CTLA-4

SERIAL NUMBER: 09612914 FILING DATE: 07/10/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09628186 FILING DATE: 07/28/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: KIT FOR RADIOLABELING LIGANDS WITH YTTRIUM-90

SERIAL NUMBER: 09635929 FILING DATE: 08/10/2000  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF PATIENTS HAVING NON-HODGKINS LYMPHOMA WITH BONE  
MARROW INVOLVEMENT WITH ANTI-CD20 ANTIBODIES

SERIAL NUMBER: 09758173 FILING DATE: 01/12/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHODS FOR TREATING B CELL LYMPHOMA USING CD80-SPECIFIC ANTIBODIES

SERIAL NUMBER: 09772938 FILING DATE: 01/31/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF CELL MALIGNANCIES USING COMBINATION OF B CELL  
DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED  
APPLICATIONS

SERIAL NUMBER: 09791551 FILING DATE: 02/26/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD FOR PREPARING ANTI-MIF ANTIBODIES

SERIAL NUMBER: 09798525 FILING DATE: 02/21/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES  
DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-  
ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 09805217 FILING DATE: 03/14/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: ANTIBODIES THAT BIND PHOSPHATIDYL SERINE AND A METHOD OF THEIR USE

SERIAL NUMBER: 09822672 FILING DATE: 04/02/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-  
CD20 FOR TREATMENT OF B CELL LYMPHOMA

SERIAL NUMBER: 09840872 FILING DATE: 04/25/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL  
NERVOUS SYSTEM LYMPHOMAS

SERIAL NUMBER: 09853580 FILING DATE: 05/14/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR  
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09853581 FILING DATE: 05/14/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR  
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09855717 FILING DATE: 05/16/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL  
DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED  
APPLICATIONS

SERIAL NUMBER: 09856534 FILING DATE: 09/04/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: TUMOR ANTIGEN- SPECIFIC ANTIBODY- GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 09874141 FILING DATE: 06/06/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: NON-AGONISTIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING,  
AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09883962 FILING DATE: 06/20/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCIES AND  
AUTOIMMUNE DISEASES USING A COLD ANTI-CD20 ANTIBODY/RADIOLABELED  
ANTI-CD22 ANTIBODY COMBINATION

015044/0873 PAGE 9

SERIAL NUMBER: 09954274 FILING DATE: 09/18/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B  
CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION

SERIAL NUMBER: 09982849 FILING DATE: 10/22/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: VARIANT IGG3 RITUXAN AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09985646 FILING DATE: 11/05/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

SERIAL NUMBER: 09986174 FILING DATE: 11/07/2001  
PATENT NUMBER: ISSUE DATE:  
TITLE: BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR  
CELL KILLING OF TARGET CELLS

SERIAL NUMBER: 10058120 FILING DATE: 01/29/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: MODIFIED ANTIBODIES AND METHODS OF USE

SERIAL NUMBER: 10073138 FILING DATE: 02/13/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN  
ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS

SERIAL NUMBER: 10096963 FILING DATE: 03/14/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN  
COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND  
RADIOTHERAPY

SERIAL NUMBER: 10109853 FILING DATE: 04/01/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN  
CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING  
THE SAME

SERIAL NUMBER: 10113929 FILING DATE: 04/02/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTIBODIES COEXPRESSED WITH GNTIII

SERIAL NUMBER: 10171680 FILING DATE: 06/17/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: HUMANIZED ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING AND  
THERAPEUTIC USE THEREOF

SERIAL NUMBER: 10171681 FILING DATE: 06/17/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATING AUTOIMMUNE DISEASES WITH HUMANIZED ANTI-CD40L ANTIBODY

015044/0873 PAGE 10

SERIAL NUMBER: 10191052 FILING DATE: 07/10/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: INHIBITION OF APOPTOSIS PROCESS AND IMPROVEMENT OF CELL PERFORMANCE

SERIAL NUMBER: 10195426 FILING DATE: 07/16/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: NEW CLINICAL PARAMETERS FOR DETERIMING HEMATOLOGIC TOXICITY PRIOR TO RADIOIMMUNOTHERAPY

SERIAL NUMBER: 10211357 FILING DATE: 08/05/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 10241832 FILING DATE: 09/12/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

SERIAL NUMBER: 10241836 FILING DATE: 09/12/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: IMMUNOREGULATORY ANTIBODIES AND USES THEREOF

SERIAL NUMBER: 10291532 FILING DATE: 11/12/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES

SERIAL NUMBER: 10295823 FILING DATE: 11/18/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: POLYCISTRONIC EXPRESSION OF ANTIBODIES

SERIAL NUMBER: 10326924 FILING DATE: 12/23/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: GENES OVEREXPRESSED BY OVARIAN CANCER AND THEIR USE IN DEVELOPING NOVEL THERAPEUTICS, ESPECIALLY ANTIBODIES

SERIAL NUMBER: 10367978 FILING DATE: 02/19/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OR THERAPEUTICS

SERIAL NUMBER: 10384356 FILING DATE: 03/10/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 10661086 FILING DATE: 09/12/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: METHOD OF PURIFYING POLYPEPTIDES BY SIMULATED MOVING BED CHROMATOGRAPHY

015044/0873 PAGE 11

SERIAL NUMBER: 10743398 FILING DATE: 12/23/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 10743739 FILING DATE: 12/24/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR  
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 60148287 FILING DATE: 08/11/1999  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF PATIENTS HAVING NON-HODGKINS LYMPHOMA WITH BONE MARROW  
INVOLVEMENT WITH ANTI-CD20 ANTIBODIES

SERIAL NUMBER: 60479910 FILING DATE: 06/20/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: USE OF DEPTH FILTRATION AND CONTINUOUS CENTRIFUGATION TO CLARIFY  
CELL SAMPLES

SERIAL NUMBER: 60510552 FILING DATE: 10/14/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: LECTIN AFFINITY PURIFICATION AND IDENTIFICATION OF PROTEINS OF  
VASCULAR TISSUE ASSOCIATED WITH A DISEASE OR DISORDER

SERIAL NUMBER: 10703669 FILING DATE: 11/10/2003  
PATENT NUMBER: ISSUE DATE:  
TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCIES AND  
AUTOIMMUNE DISEASES USING A COLD ANTI-CD20 ANTIBODY/RADIOLABELED  
ANTI-CD22 ANTIBODY COMBINATION

SERIAL NUMBER: 10796158 FILING DATE: 03/10/2004  
PATENT NUMBER: ISSUE DATE:  
TITLE: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES

SERIAL NUMBER: 10871261 FILING DATE: 06/21/2004  
PATENT NUMBER: ISSUE DATE:  
TITLE: USE OF DEPTH FILTRATION IN SERIES WITH CONTINUOUS CENTRIFUGATION TO  
CLARIFY MAMMALIAN CELL CULTURES

SERIAL NUMBER: 10058069 FILING DATE: 01/29/2002  
PATENT NUMBER: ISSUE DATE:  
TITLE: ENGINEERED TETRAVALENT ANTIBODIES AND METHODS OF USE

SERIAL NUMBER: 07680808 FILING DATE: 03/12/1991  
PATENT NUMBER: 5270202 ISSUE DATE: 12/14/1993  
TITLE: ANTI-IDIOTYPE ANTIBODIES TO HUMAN MELANOMA-ASSOCIATED PROTEOGLYCAN  
ANTIGEN

SERIAL NUMBER: 07919787 FILING DATE: 07/24/1992  
PATENT NUMBER: 5585103 ISSUE DATE: 12/17/1996  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08147696	FILING DATE: 11/03/1993
PATENT NUMBER: 5648267	ISSUE DATE: 07/15/1997
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME	
SERIAL NUMBER: 08379072	FILING DATE: 01/25/1995
PATENT NUMBER: 5658570	ISSUE DATE: 08/19/1997
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY	
SERIAL NUMBER: 08478039	FILING DATE: 06/07/1995
PATENT NUMBER: 5681722	ISSUE DATE: 10/28/1997
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY	
SERIAL NUMBER: 08481869	FILING DATE: 06/07/1995
PATENT NUMBER: 5693780	ISSUE DATE: 12/02/1997
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY	
SERIAL NUMBER: 08472311	FILING DATE: 06/07/1995
PATENT NUMBER: 5695770	ISSUE DATE: 12/09/1997
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES	
SERIAL NUMBER: 08351001	FILING DATE: 12/07/1994
PATENT NUMBER: 5709860	ISSUE DATE: 01/20/1998
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES	
SERIAL NUMBER: 08484334	FILING DATE: 06/07/1995
PATENT NUMBER: 5733779	ISSUE DATE: 03/31/1998
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME	
SERIAL NUMBER: 08476349	FILING DATE: 06/07/1995
PATENT NUMBER: 5750105	ISSUE DATE: 05/12/1998
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY	
SERIAL NUMBER: 08476237	FILING DATE: 06/07/1995
PATENT NUMBER: 5756096	ISSUE DATE: 05/26/1998
TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY	
SERIAL NUMBER: 08488376	FILING DATE: 06/07/1995
PATENT NUMBER: 5811524	ISSUE DATE: 09/22/1998
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF	
SERIAL NUMBER: 08819866	FILING DATE: 03/14/1997
PATENT NUMBER: 5830698	ISSUE DATE: 11/03/1998
TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING THE SAME	

**THIS PAGE BLANK (USPTO)**

SERIAL NUMBER: 08634223 FILING DATE: 04/18/1996  
PATENT NUMBER: 5840298 ISSUE DATE: 11/24/1998  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO  
RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE  
THEREOF

SERIAL NUMBER: 08634224 FILING DATE: 04/18/1996  
PATENT NUMBER: 5866125 ISSUE DATE: 02/02/1999  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO  
RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE  
THEREOF

SERIAL NUMBER: 08634400 FILING DATE: 04/18/1996  
PATENT NUMBER: 5939068 ISSUE DATE: 08/17/1999  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO  
RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE  
THEREOF

SERIAL NUMBER: 08635878 FILING DATE: 04/18/1996  
PATENT NUMBER: 5955364 ISSUE DATE: 09/21/1999  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO  
RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE  
THEREOF

SERIAL NUMBER: 09023715 FILING DATE: 02/13/1998  
PATENT NUMBER: 5998144 ISSUE DATE: 12/07/1999  
TITLE: METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN CELLS  
VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING THE SAME

SERIAL NUMBER: 08554840 FILING DATE: 11/07/1995  
PATENT NUMBER: 6001358 ISSUE DATE: 12/14/1999  
TITLE: HUMANIZED ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING AND  
THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09013092 FILING DATE: 01/26/1998  
PATENT NUMBER: 6017733 ISSUE DATE: 01/25/2000  
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION  
STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND  
EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 08487550 FILING DATE: 06/07/1995  
PATENT NUMBER: 6113898 ISSUE DATE: 09/05/2000  
TITLE: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS  
EXPRESSING SAID ANTIBODIES

SERIAL NUMBER: 08523894 FILING DATE: 09/06/1995  
PATENT NUMBER: 6136310 ISSUE DATE: 10/24/2000  
TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09280999 FILING DATE: 03/30/1999  
PATENT NUMBER: 6159730 ISSUE DATE: 12/12/2000  
TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION  
STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND  
EXPRESSION VECTOR SYSTEMS COMPRISING SAME



015044/0873 PAGE 14

SERIAL NUMBER: 09024220 FILING DATE: 02/17/1998  
PATENT NUMBER: 6197311 ISSUE DATE: 03/06/2001  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 09261207 FILING DATE: 03/03/1999  
PATENT NUMBER: 6207858 ISSUE DATE: 03/27/2001  
TITLE: REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES

SERIAL NUMBER: 08449728 FILING DATE: 05/24/1995  
PATENT NUMBER: 6270769 ISSUE DATE: 08/07/2001  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 09259347 FILING DATE: 03/01/1999  
PATENT NUMBER: 6300143 ISSUE DATE: 10/09/2001  
TITLE: ELECTROCHEMILUMINESCENT ASSAYS FOR EUKARYOTIC CELLS

SERIAL NUMBER: 09335697 FILING DATE: 06/18/1999  
PATENT NUMBER: 6413771 ISSUE DATE: 07/02/2002  
TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO  
RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPUTIC USE  
THEREOF

SERIAL NUMBER: 09343485 FILING DATE: 06/30/1999  
PATENT NUMBER: 6413777 ISSUE DATE: 07/02/2002  
TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN  
CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING  
THE SAME

SERIAL NUMBER: 08925339 FILING DATE: 09/08/1997  
PATENT NUMBER: 6440418 ISSUE DATE: 08/27/2002  
TITLE: METHODS OF TREATING AUTOIMMUNE DISEASES WITH GP39-SPECIFIC  
ANTIBODIES

SERIAL NUMBER: 09625856 FILING DATE: 07/26/2000  
PATENT NUMBER: 6451284 ISSUE DATE: 09/17/2002  
TITLE: NEW CLINICAL PARAMETERS FOR DETERMINING HEMATOLOGIC TOXICITY PRIOR  
TO RADIOIMMUNOTHERAPY

SERIAL NUMBER: 09332595 FILING DATE: 06/14/1999  
PATENT NUMBER: 6506383 ISSUE DATE: 01/14/2003  
TITLE: HUMANIZED ANTIBODIES OF HUMAN GP39, COMPOSITIONS CONTAINING AND  
THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09383916 FILING DATE: 08/26/1999  
PATENT NUMBER: 6709654 ISSUE DATE: 03/23/2004  
TITLE: TREATMENT OF PSORIASIS USING ANTI-B7.1(CD80) ANTIBODIES

SERIAL NUMBER: 09740003 FILING DATE: 12/20/2000  
PATENT NUMBER: 6733763 ISSUE DATE: 05/11/2004  
TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

015044/0873 PAGE 15

SHAREILL COLES, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

## BOX ASSIGNMENTS

700106103

DO NOT USE FOR TRADEMARKS

RECORDATION FORM COVER SHEET  
PATENT APPLICATIONS & PATENTS ONLYTO THE DIRECTOR OF THE US PATENT AND TRADEMARK OFFICE:  
SIR: PLEASE RECORD THE ATTACHED ORIGINAL DOCUMENTS OR COPY THEREOF.

## 1. NAME OF CONVEYING PARTY(IES) (ASSIGNORS(S)):

1. Idec Pharmaceuticals Corporation

3.

5.

7.

2.

4.

6.

8.

ADDITIONAL NAME(S) OF CONVEYING PARTY(IES) ATTACHED? ☐ YES ☒ NO

## 2. PARTY(IES) (ASSIGNEE(S)) RECEIVING INTEREST:

NAME: Biogen Idec Inc.

ADDRESS: 3030 Callan Road, San Diego, California 92121

ADDITIONAL NAME(S) & ADDRESS(ES) ATTACHED? ☐ YES ☒ NO

## 3. NATURE OF CONVEYANCE (DOCUMENT):

(Submit herewith only one document for recordation—multiple copies of same Assignment signed by different inventors is one document)☐ ASSIGNMENT OF☐ WHOLE☐ PART INTEREST☐ ORIGINAL☐ FACSIMILE/PHOTOCOPY☒ CHANGE OF NAME☐ VERIFIED TRANSLATION☐ SECURITY ☐ MERGER☐ OTHER:

EXEC. DATE: 11/12/03

EXECUTION DATE(S) ON THE DECLARATION IF FILED HEREWITH: (NOTE: IF DATES ON DECLARATION AND ASSIGNMENT DIFFER SEE ATTY!)

4.5 APPL. NO.(S) OR PAT NO.(S). OTHERS ON ADDITIONAL SHEET(S) attached? ☒ YES ☐ NO

A. PAT. APP. NO.(S) series code/serial no	M#	1 <sup>st</sup> INVENTOR if not in item 1	B. PATENT NO(S)	M#	1 <sup>st</sup> INVENTOR if not in item 1
--	----	--	-----------------	----	--

See Attached

Appendix (4 pages)

See Attached

Appendix

5. Name & Address of Party to Whom Correspondence  
Concerning Document Should be Mailed:Pillsbury Winthrop LLP  
Intellectual Property Group  
P.O. Box 10500 McLean, VA 22102

6. NUMBER INVOLVED:

APPLNS 112 + PATS 34 = TOTAL = 146

7. AMOUNT OF FEE DUE: (Code 8021)

ABOVE TOTAL x \$40 = \$5840

5.5 ATTY DKT:

P 037003-0000051

MATTER NO.

CLIENT REF.

8. PLEASE CHARGE TO OUR DEPOSIT ACCOUNT  
NUMBER: 03-3975

UNDER ORDER NO

037003

0000051

dup. sheet not required

CLIENT NO.

MATTER NO.

9. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

10. Total number of pages including this  
cover sheet, attachments and document  
(do not file dup. Cover sheet)

7

Signature

Attorney: Thomas A. Cawley, Jr., Ph.D.

Reg. No. 40944

Atty/Sec: TAC/JBM:sl

TEL: (703) 905-2144

Date: August 6, 2004

FAX: (703) 905-2500

FILE WITH PTO RETURN RECEIPT (PAT-103A)

CH \$5800.00 033975 07431426

## APPENDIX

Patents

Matter No.	Serial No.	Filing Date	Patent No.	Issue Date
281199	07/680,808	March 12, 1991	5,270,202	December 14, 1993
275979	07/919,787	July 24, 1992	5,585,103	December 17, 1996
275402	08/147,696	November 3, 1993	5,648,267	July 15, 1997
275715	08/379,072	January 25, 1995	5,658,570	August 19, 1997
275655	08/478,039	June 7, 1995	5,681,722	October 28, 1997
275656	08/481,869	June 7, 1995	5,693,780	December 2, 1997
275658	08/472,311	June 7, 1995	5,695,770	December 9, 1997
275799	08/351,001	December 7, 1994	5,709,860	January 20, 1998
275403	08/484,334	June 7, 1995	5,733,779	March 31, 1998
275657	08/476,349	June 7, 1995	5,750,105	May 12, 1998
275973	08/476,237	June 7, 1995	5,756,096	May 26, 1998
275757	08/488,376	June 7, 1995	5,811,524	September 22, 1998
275843	08/819,866	March 14, 1997	5,830,698	November 3, 1998
275676	08/634,223	April 18, 1996	5,840,298	November 24, 1998
275679	08/634,224	April 18, 1996	5,866,125	February 2, 1999
275677	08/634,400	April 18, 1996	5,939,068	August 17, 1999
275678	08/635,878	April 18, 1996	5,955,364	September 21, 1999
275844	09/023,715	February 13, 1998	5,998,144	December 7, 1999
275832	08/554,840	November 7, 1995	6,001,358	December 14, 1999
275404	09/013,092	January 26, 1998	6,017,733	January 25, 2000
275942	08/487,550	June 7, 1995	6,113,898	September 5, 2000
275680	08/523,894	September 6, 1995	6,136,310	October 24, 2000
275732	09/280,999	March 30, 1999	6,159,730	December 12, 2000
275801	09/024,220	February 17, 1998	6,197,311	March 6, 2001
275407	09/261,207	March 3, 1999	6,207,858	March 27, 2001
276461	08/449,728	May 24, 1995	6,270,769	August 7, 2001
275831	09/259,347	March 1, 1999	6,300,143	October 9, 2001
275759	09/335,697	June 18, 1999	6,413,771	July 2, 2002
275807	09/343,485	June 30, 1999	6,413,777	July 2, 2002
275833	08/925,339	September 8, 1997	6,440,418	August 27, 2002
275983	09/625,856	July 26, 2000	6,451,284	September 17, 2002
275683	09/332,595	June 14, 1999	6,506,383	January 14, 2003
275716	09/383,916	August 26, 1999	6,709,654	March 23, 2004
275802	09/740,003	December 20, 2000	6,733,763	May 11, 2004

## APPENDIX

Applications

Matter No.	Serial No.	Filing Date	Status
281198	07/431,426	November 3, 1989	ABANDONED
275969	07/735,064	July 25, 1991	ABANDONED
275978	07/735,069	July 25, 1991	ABANDONED
275970	07/856,281	March 23, 1992	ABANDONED
275971	07/912,292	July 10, 1992	ABANDONED
275730	07/977,691	November 13, 1992	ABANDONED
275800	08/476,674	June 7, 1995	ABANDONED
275943	08/746,361	November 8, 1996	ABANDONED
275999	08/933,359	September 18, 1997	ABANDONED
275974	09/082,472	May 21, 1998	ABANDONED
277092	09/149,479	September 8, 1998	ABANDONED
275733	09/615,796	July 13, 2000	ABANDONED
280601	09/834,933	April 16, 2001	ABANDONED
280614	09/850,165	May 8, 2001	ABANDONED
280631	09/877,065	June 11, 2001	ABANDONED
282604	09/971,631	October 9, 2001	ABANDONED
277093	60/057,831	September 8, 1997	LAPSED
275531	60/109,607	November 23, 1998	LAPSED
275820	60/134,848	May 19, 1999	LAPSED
275980	60/148,288	August 11, 1999	LAPSED
275842	60/185,390	February 28, 2000	LAPSED
276451	60/189,050	March 14, 2000	LAPSED
275675	60/193,467	March 31, 2000	LAPSED
275477	60/199,365	April 25, 2000	LAPSED
275545	60/209,584	June 6, 2000	LAPSED
275474	60/210,451	June 9, 2000	LAPSED
275490	60/212,668	June 20, 2000	LAPSED
275819	60/213,252	June 22, 2000	LAPSED
275471	60/217,706	July 12, 2000	LAPSED
275435	60/233,607	September 18, 2000	LAPSED
275544	60/233,625	September 18, 2000	LAPSED
275473	60/241,022	October 20, 2000	LAPSED
276519	60/257,147	December 22, 2000	LAPSED
277109	60/264,318	January 29, 2001	LAPSED
280060	60/280,139	April 2, 2001	LAPSED
280616	60/300,063	June 25, 2001	LAPSED
277149	60/303,813	July 10, 2001	LAPSED
282445	60/331,187	November 9, 2001	LAPSED
279155	60/331,481	November 16, 2001	LAPSED
280678	60/341,858	December 21, 2001	LAPSED
280677	60/341,860	December 21, 2001	LAPSED
280703	60/357,140	February 19, 2002	LAPSED
280692	60/367,727	March 28, 2002	LAPSED
280750	60/381,328	May 20, 2002	LAPSED

## APPENDIX

Matter No.	Serial No.	Filing Date	Status
280757	60/386,746	June 10, 2002	LAPSED
280759	60/386,747	June 10, 2002	LAPSED
280761	60/386,748	June 10, 2002	LAPSED
280760	60/386,759	June 10, 2002	LAPSED
280724	60/390,191	June 21, 2002	LAPSED
280763	60/396,082	July 17, 2002	LAPSED
280767	60/396,141	July 17, 2002	LAPSED
280764	60/396,255	July 17, 2002	LAPSED
280758	60/400,687	August 5, 2002	LAPSED
280772	60/405,318	August 23, 2002	LAPSED
280773	60/405,319	August 23, 2002	LAPSED
280765	60/410,506	September 13, 2002	LAPSED
291922	60/427,564	November 20, 2002	LAPSED
291923	60/428,274	November 22, 2002	LAPSED
291918	60/452,928	March 10, 2003	LAPSED
277113	09/238,741	January 28, 1999	PENDING
275818	09/259,337	March 1, 1999	PENDING
275984	09/259,338	March 1, 1999	PENDING
275478	09/435,992	November 8, 1999	PENDING
275532	09/447,594	November 23, 1999	PENDING
275681	09/576,424	May 22, 2000	PENDING
275543	09/612,914	July 10, 2000	PENDING
280721	09/628,186	July 28, 2000	PENDING
275726	09/635,929	August 10, 2000	PENDING
276603	09/758,173	January 12, 2001	PENDING
276658	09/772,938	January 31, 2001	PENDING
277869	09/791,551	February 26, 2001	PENDING
277931	09/798,525	February 21, 2001	PENDING
279190	09/805,217	March 14, 2001	PENDING
280062	09/822,672	April 2, 2001	PENDING
280609	09/840,872	April 25, 2001	PENDING
280618	09/853,580	May 14, 2001	PENDING
280617	09/853,581	May 14, 2001	PENDING
280623	09/855,717	May 16, 2001	PENDING
280624	09/856,534	September 4, 2001	PENDING
280632	09/874,141	June 6, 2001	PENDING
280637	09/883,962	June 20, 2001	PENDING
280657	09/954,274	September 18, 2001	PENDING
280728	09/982,849	October 22, 2001	PENDING
280731	09/985,646	November 5, 2001	PENDING
280732	09/986,174	November 7, 2001	PENDING
280727	10/058,069	January 29, 2002	PENDING
280743	10/058,120	January 29, 2002	PENDING
280705	10/073,138	February 13, 2002	PENDING
280745	10/096,963	March 14, 2002	PENDING

## APPENDIX

Matter No.	Serial No.	Filing Date	Status
280747	10/109,853	April 1, 2002	PENDING
280748	10/113,929	April 2, 2002	PENDING
280749	10/171,680	June 17, 2002	PENDING
280752	10/171,681	June 17, 2002	PENDING
291568	10/191,052	July 10, 2002	PENDING
280766	10/195,426	July 16, 2002	PENDING
280771	10/211,357	August 5, 2002	PENDING
291806	10/241,832	September 12, 2002	PENDING
291807	10/241,836	September 12, 2002	PENDING
291872	10/291,532	November 12, 2002	PENDING
291921	10/295,823	November 18, 2002	PENDING
301015	10/326,924	December 23, 2002	PENDING
301988	10/367,978	February 19, 2003	PENDING
302468	10/384,356	March 10, 2003	PENDING
305940	10/661,086	September 12, 2003	PENDING
307430	10/743,398	December 23, 2003	PENDING
307368	10/743,739	December 24, 2003	PENDING
276000	60/148,287	August 11, 1999	PENDING
304387	60/479,910	June 20, 2003	PENDING
306302	60/510,552	October 14, 2003	PENDING
306645	10/703,669	November 10, 2003	PENDING
308678	10/796,158	March 10, 2004	PENDING
310260	10/871,261	June 21, 2004	PENDING